You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials
|
|---|---|
| Published in |
BMC Cancer, April 2019
|
| DOI | 10.1186/s12885-019-5507-6 |
| Pubmed ID | |
| Authors |
Martin Connock, Xavier Armoiry, Alexander Tsertsvadze, G. J. Melendez-Torres, Pamela Royle, Lazaros Andronis, Aileen Clarke |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 50 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 7 | 14% |
| Student > Master | 6 | 12% |
| Researcher | 4 | 8% |
| Unspecified | 3 | 6% |
| Student > Bachelor | 2 | 4% |
| Other | 9 | 18% |
| Unknown | 19 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 24% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 14% |
| Nursing and Health Professions | 5 | 10% |
| Unspecified | 3 | 6% |
| Business, Management and Accounting | 1 | 2% |
| Other | 4 | 8% |
| Unknown | 18 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 July 2023.
All research outputs
#6,782,156
of 24,176,645 outputs
Outputs from BMC Cancer
#1,694
of 8,591 outputs
Outputs of similar age
#121,117
of 354,595 outputs
Outputs of similar age from BMC Cancer
#47
of 216 outputs
Altmetric has tracked 24,176,645 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 8,591 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 354,595 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 216 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.